137 related articles for article (PubMed ID: 37017026)
1. Real world use of dolutegravir two drug regimens: Erratum.
AIDS; 2023 May; 37(6):1019. PubMed ID: 37017026
[No Abstract] [Full Text] [Related]
2. Low-cost urine tenofovir assay to triage dolutegravir resistance testing.
Martinson T; Nwogu-Attah J; Spinelli M; Gandhi M
Lancet HIV; 2024 May; 11(5):e282-e283. PubMed ID: 38461845
[No Abstract] [Full Text] [Related]
3. The promise of paediatric dolutegravir.
Golin R; Samuel JM; Phelps BR; Persaud U; Malati CY; Siberry GK
J Int AIDS Soc; 2021 Jan; 24(1):e25660. PubMed ID: 33522081
[No Abstract] [Full Text] [Related]
4. Engendering health systems in response to national rollout of dolutegravir-based regimens among women of childbearing potential: a qualitative study with stakeholders in South Africa and Uganda.
Alhassan Y; Twimukye A; Malaba T; Orrell C; Myer L; Waitt C; Lamorde M; Kambugu A; Reynolds H; Khoo S; Taegtmeyer M
BMC Health Serv Res; 2020 Aug; 20(1):705. PubMed ID: 32738918
[TBL] [Abstract][Full Text] [Related]
5. Impact of Treatment Adherence on Efficacy of Dolutegravir + Lamivudine and Dolutegravir + Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Week 144 Analysis of the GEMINI-1 and GEMINI-2 Clinical Studies.
Fernvik E; Sierra Madero J; Espinosa N; Gulminetti R; Hagins D; Tsai HC; Man C; Sievers J; Grove R; Zolopa A; Wynne B; van Wyk J; Ait-Khaled M
J Acquir Immune Defic Syndr; 2023 Nov; 94(3):e9-e12. PubMed ID: 37850985
[No Abstract] [Full Text] [Related]
6. HIV-1 diversity and the implementation of integrase strand-transfer inhibitors as part of combination antiretroviral therapy.
Mikasi SG; Ikomey GM; Obasa AE; Cloete R; Jacobs GB
S Afr Med J; 2020 Aug; 110(9):13071. PubMed ID: 32880259
[No Abstract] [Full Text] [Related]
7. Dolutegravir-Based Antiretroviral Regimens for HIV Liver Transplant Patients in Real-Life Settings.
Cattaneo D; Sollima S; Meraviglia P; Milazzo L; Minisci D; Fusi M; Filice C; Gervasoni C
Drugs R D; 2020 Jun; 20(2):155-160. PubMed ID: 32189238
[TBL] [Abstract][Full Text] [Related]
8. Compelling evidence for unconditional shift to dolutegravir.
Steegen K; Hans L
Lancet HIV; 2022 Aug; 9(8):e523-e524. PubMed ID: 35905750
[No Abstract] [Full Text] [Related]
9. Dolutegravir drug-resistance monitoring in Africa.
Kouamou V; Inzaule S; Manasa J
Lancet HIV; 2021 Nov; 8(11):e664-e666. PubMed ID: 34735801
[No Abstract] [Full Text] [Related]
10. Dosing of Dolutegravir in TB/HIV Coinfected Patients on Rifampicin: Twice Is (Always) Better Than Once.
Cattaneo D; Riva A; Columpsi P; Lapadula G; Filice C; Gervasoni C
J Acquir Immune Defic Syndr; 2020 Jul; 84(3):e17-e20. PubMed ID: 32205722
[No Abstract] [Full Text] [Related]
11. Concerns and clarifications regarding the article 'Virological, weight, and drug resistance outcomes among patients initiating a dolutegravir-based first line ART regimen in Zimbabwe'.
Karabay O
AIDS; 2024 Jul; 38(8):1273. PubMed ID: 38814717
[No Abstract] [Full Text] [Related]
12. Increase in visceral adipose tissue in a woman living with HIV after introduction of integrase strand transfer inhibitor.
Piacentini D; Lanzafame M; Rizzardo S; Chiesi S; Lattuada E; Mehrabi S; Zamboni G; Mazzi R; Tacconelli E; Vento S
Int J STD AIDS; 2020 Dec; 31(14):1407-1410. PubMed ID: 33081650
[TBL] [Abstract][Full Text] [Related]
13. Dolutegravir for children with HIV-associated tuberculosis.
Meyers T; Krogstad P
Lancet HIV; 2022 Sep; 9(9):e599-e600. PubMed ID: 35868340
[No Abstract] [Full Text] [Related]
14. High performance of integrase genotyping on diverse HIV-1 clades circulating in Cameroon: toward a successful transition to dolutegravir-based regimens in low and middle-income countries.
Fokam J; Ngoufack Jagni Semengue E; Armenia D; Takou D; Dambaya B; Teto G; Chenwi CA; Nka AD; Beloumou GA; Ndjeyep SCD; Tchouaket MCT; Fainguem N; Sosso SM; Colizzi V; Perno CF; Ndjolo A; Ceccherini-Silberstein F; Santoro MM
Diagn Microbiol Infect Dis; 2022 Feb; 102(2):115574. PubMed ID: 34864527
[TBL] [Abstract][Full Text] [Related]
15. Mutations in the HIV-1 3'-Polypurine Tract Can Confer Dolutegravir Resistance.
Dekker JG; Klaver B; Berkhout B; Das AT
Antimicrob Agents Chemother; 2022 Jan; 66(1):e0102721. PubMed ID: 34633840
[No Abstract] [Full Text] [Related]
16. Two drugs regimens for HIV.
Waters L; Church H
Curr Opin Infect Dis; 2020 Feb; 33(1):28-33. PubMed ID: 31834030
[TBL] [Abstract][Full Text] [Related]
17. Should we continue to use tenofovir disoproxil fumarate/lamivudine/dolutegravir for treatment of pregnant women? Interpreting the PROMISE trial.
Hill AM; Elbirt D
AIDS; 2024 Jul; 38(9):1430-1431. PubMed ID: 38932745
[No Abstract] [Full Text] [Related]
18. Increase in Body Mass Index in Children With HIV, Switched to Tenofovir Alafenamide Fumarate or Dolutegravir Containing Antiretroviral Regimens.
Yeoh DK; Campbell AJ; Bowen AC
Pediatr Infect Dis J; 2021 May; 40(5):e215-e216. PubMed ID: 33847305
[No Abstract] [Full Text] [Related]
19. Abacavir/dolutegravir/lamivudine single-tablet regimen: a review of its use in HIV-1 infection.
Greig SL; Deeks ED
Drugs; 2015 Apr; 75(5):503-14. PubMed ID: 25698454
[TBL] [Abstract][Full Text] [Related]
20. Is resistance to dolutegravir possible when this drug is used in first-line therapy?
Mesplède T; Wainberg MA
Viruses; 2014 Aug; 6(9):3377-85. PubMed ID: 25166745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
